Tianci International Pharmaceutical
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Tianci International Pharmaceutical - overview
Established
2013
Location
Shanghai, Shanghai, China
Primary Industry
Pharmaceuticals
About
Establishd in 2013 and based in Shanghai, China, Tianci International Pharmaceutical operates as a pharmaceutical industry chain aggregation platform that focuses on drug research and development technical support. In March 2017, the company closed a round of series D funding. The company focuses on the research and development of new drugs and APIs. The products mainly include innovative drugs and generic drugs.
Innovative drugs include therapeutic biological products, Class 1 innovative thrombolytic drugs HTUPA, IDO inhibitors, and mannooligosaccharide diacid capsules. The generic drug is amlodipine besylate tablets, which are used to treat cardiovascular diseases such as hypertension and coronary heart disease. The company generates revenue by providing new drugs and APIs.
Current Investors
Goldwell Capital, GTJA Innovation Investment, Haisi Chuanzong Investment Management
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.wepharma.cn
Company Stage
Series D
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.